Lineage cell therapeutics, inc. (BTX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
REVENUES:
Grant revenue

2,037

3,572

1,666

-

-

-

-

-

-

-

-

Royalties from product sales and license fees

1,221

392

389

-

-

-

-

-

-

-

-

Grant revenue

-

-

-

3,671

4,502

3,297

1,573

2,222

2,767

2,336

546

License fees

-

-

-

-

-

-

-

899

263

292

292

Royalties from product sales and license fees

-

-

-

544

719

398

367

541

756

945

1,079

Subscription and advertisement revenues

-

691

1,395

972

1,357

1,173

2,218

-

-

-

-

Sale of research products and services

257

333

8

-

-

-

-

-

-

-

-

Total revenues

3,515

4,988

3,458

-

-

-

-

-

-

-

-

Sale of research products and services

-

-

-

736

458

376

276

251

646

133

5

Total revenues

-

-

-

5,923

7,036

5,244

4,434

3,915

4,434

3,708

1,925

Cost of sales

412

302

168

358

1,107

837

793

434

79

27

-

Gross profit

3,103

4,686

3,290

5,565

5,929

4,407

3,641

3,481

4,354

3,680

-

OPERATING EXPENSES:
Research and development

17,948

20,955

24,024

36,106

42,604

37,533

26,609

18,116

13,699

8,191

-3,181

Acquired in-process research and development

-

800

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

-

-

-

-

-

-

17,459

0

0

-

-

General and administrative

24,031

24,726

19,922

28,426

29,134

17,556

15,559

10,365

9,341

5,341

-2,263

Total operating expenses

41,979

46,481

43,946

64,532

71,738

55,089

59,627

28,481

23,041

13,532

5,445

Gain on sale of assets

-

-

1,754

0

0

-

-

-

-

-

-

Loss from operations

-38,876

-41,795

-38,902

-58,967

-65,809

-50,682

-55,986

-25,000

-18,686

-9,852

-3,520

OTHER INCOME/(EXPENSES):
Interest income (expense), net

1,685

711

-692

-747

-340

-89

-

-

-

-

-

Gain on sale of marketable equity securities

2,421

-

-

-

-

-

-

-

-

-

-

Gain on sale of AgeX shares and deconsolidation of AgeX

-

78,511

-

-

-

-

-

-

-

-

-

Interest income/(expense), net

-

-

-

-

-

-

0

19

29

-124

-1,653

BioTimes share of losses and impairment in equity method investment in Ascendance

-

-

-

-4,671

-35

0

0

-

-

-

-

Gain on sale of shares and deconsolidation

-

-

-

-

-

0

-

-

-

-

-

Loss on equity method investment in Asterias at fair value

-

-

-

-

-

0

-

-

-

-

-

Unrealized (loss) gain on marketable equity securities

-2,898

1,158

-

-

-

-

-

-

-

-

-

Loss on equity method investment in AgeX at fair value

-

-4,181

-

-

-

-

-

-

-

-

-

Unrealized gain on warrant liability

611

384

-

-

-

-

-

-

-

-

-

Loss on extinguishment of related party convertible debt

-

-

-2,799

0

0

-

-

-

-

-

-

Gain on investment

-

-

-

0

3,694

0

0

-

-

-

-

Other (expense) income, net

2,532

-1,699

1,449

-403

-160

-384

-204

-

-

-

-

(Loss)/gain on sale or write off of fixed assets

-

-

-

-

-

-

-

-6

-6

0

0

Modification cost of warrants

-

-

-

-

-

-

-

-

-

-2,142

0

Other income, net

-

-

-

-

-

-

-

-317

219

-68

30

Total other (expense) income, net

19,642

-5,335

15,613

77,588

3,159

-473

-204

-305

242

-2,335

-1,623

(LOSS)/INCOME BEFORE INCOME TAXES

-19,234

-47,130

-23,289

18,621

-62,650

-51,155

-56,191

-25,305

-18,443

-

-

Deferred income tax benefit

-

-

-

0

-4,516

-7,376

-3,281

0

0

-

-

Deferred income tax benefit

7,407

346

-

-

-

-

-

-

-

-

-

NET (LOSS)/INCOME

-11,827

-46,784

-23,289

18,621

-58,134

-43,779

-52,910

-25,305

-18,443

-12,187

-5,143

Net loss attributable to noncontrolling interest

-118

-794

-3,313

-14,951

-11,143

-7,367

-9,026

-3,880

-1,928

-1,002

0

NET (LOSS)/INCOME ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC.

-11,709

-45,990

-19,976

33,572

-46,991

-36,412

-43,883

-21,425

-16,515

-11,184

-5,144

NET (LOSS)/INCOME PER COMMON SHARE:
Dividends on preferred shares

-

-

-

0

-415

87

0

0

-

-

-

NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS

-

-

-

33,572

-47,406

-36,499

-43,883

-21,425

-

-

-

Unrealized loss on available-for-sale assets

-

-

-

-

-

-

-

-

0

-

-

Foreign currency translation (loss)/gain

-

-

-

-

-

-

-

-

-1,020

897

-

Foreign currency translation gain/(loss)

-

-

-

-

-

-

-

-

-

-

0

TOTAL COMPREHENSIVE NET LOSS

-

-

-

-

-

-

-

-

-17,535

-10,287

-5,144

BASIC AND DILUTED

-0.08

-0.36

-0.17

-

-

-

-0.81

-0.44

-0.35

-0.28

-0.18

BASIC

-

-

-

0.35

-0.59

-0.55

-

-

-

-

-

DILUTED

-

-

-

0.34

-0.59

-0.55

-

-

-

-

-

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
BASIC

-

-

-

97,316

79,711

66,467

-

-

-

-

-

DILUTED

-

-

-

99,553

79,711

66,467

-

-

-

-

-

BASIC AND DILUTED

145

126

114,476

-

-

-

54,226

49,213

47,053

40,266

-

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED (in shares)

-

-

-

-

-

-

-

-

-

-

29,295

OncoCyte Corporation [Member]
Gain on sale of shares and deconsolidation

-

-

71,697

-

-

-

-

-

-

-

-

(Loss) gain on equity method investment

-

-

2,900

-

-

-

-

-

-

-

-

Gain on equity method investment

546

-

-

-

-

-

-

-

-

-

-

Unrealized gain (loss) on equity method investment

8,001

-47,985

-

-

-

-

-

-

-

-

-

Asterias Biotherapeutics [Member]
(Loss) gain on equity method investment

-

-

-51,107

-

-

-

-

-

-

-

-

Unrealized gain (loss) on equity method investment

6,744

-35,449

-

-

-

-

-

-

-

-

-

Ascendance Biotechnology, Inc [Member]
Gain on sale of equity method investment

-

3,215

-

-

-

-

-

-

-

-

-